All News

pills.bottle.hand__0.jpg

Polypharmacy Impairs Rheumatoid Arthritis Outcomes

Jack Cush, MD

A French early rheumatoid arthritis (RA) study has shown that polypharmacy (PP) was associated with significant lower treatment responses and more serious adverse events (SAEs). 

Read Article
CART

CAR-T Product Shows Early Promise in Lupus

Five patients with systemic lupus erythematosus (SLE) in China have been treated with a potentially groundbreaking form of chimeric antigen receptor (CAR) T-cell therapy, researchers reported, with encouraging results after 3 months.

Read Article
GCA temporal artery

Methylprednisolone plus Methotrexate in Giant Cell Arteritis

Jack Cush, MD

What is the optimal glucocorticoids (GC) regimen in giant cell arteritis (GCA)? Does methotrexate (MTX) work in GCA?  

Read Article
lung%2Cbright.jpg

Scleroderma-associated Interstitial Lung Disease

Marcy B. Bolster, MD

While we know there are certain clinical features serving as predictors that patients with SSc may develop ILD, including diffuse skin disease and serologies such as anti-Scl-70 and Th/To antibodies, it is imperative that clinicians consider that any patient, particularly early in their disease course (5 years of disease since the first non-Raynaud phenomenon symptom) could develop ILD. 

Read Article
RheumNow Podcast square

Big Fat FDA Pink Slip (9.19.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip. 

Read Article
Monthly survey - 351 ArthritisPower #RA Registry pts reported 523 nonserious infxns (31% ; most URI), few resulted in ED or hospitalization. But NSIA led to missed work (37%) or RA Rx interruptions (26%) and more fatigue. NSIE may contribute to more disease flares https://t.co/Al5B5oxvFg
Dr. John Cush RheumNow ( View Tweet)
DERM on RheumNow Podcast (September 2025) Content curated for dermatologists and skin deep HCPs – on Psoriasis, CLE, vasculitis, HS and dermatology drugs use, efficacy and side effects and more. https://t.co/zZpheX1epS https://t.co/uOd9Gy0V2E

Links:

Dr. John Cush RheumNow ( View Tweet)
Scleroderma-associated Interstitial Lung Disease Since the first placebo-controlled randomized trial published nearly 20 years ago for the treatment of patients with SSc-ILD, evaluating cyclophosphamide vs. placebo, there have been several other randomized studies to guide the https://t.co/Dh7XpP6qhF
Dr. John Cush RheumNow ( View Tweet)
Big Fat FDA Pink Slip (9.19.2025) Dr. Jack Cush reviews the news and journal reports from this week on RheumNow. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip. https://t.co/Za39hxI8Qf https://t.co/yN4K9tOuTt

Links:

Dr. John Cush RheumNow ( View Tweet)
Should we be "scoring" comorbidity to predict outcomes? SLE metanalysis looked at Charlson Comorbidity index (CCI). 3 RCTs, 1175 SLE pts show higher CCI scores predicts increased all-cause mortality (OR 3.92(95% CI: 2.74–5.60) https://t.co/LXfsGo9iJq https://t.co/eK31lnFrJk

Links:

Dr. John Cush RheumNow ( View Tweet)
Post hoc analyses of (FUTURE 5) 541 active PsA pts Rx w/ secukinumab shows NO radiographic progression through 2 years of SEC was assoc with achieving LDA at Week 104. https://t.co/ZeI9z4Civa https://t.co/LCI6kZ1z0v

Links:

Dr. John Cush RheumNow ( View Tweet)
Did Hydroxychloroquine Reduce COVID-19 Mortality? A multicenter study investigated the association between hydroxychloroquine (HCQ) dosage and COVID-19 mortality among hospitalized patients from multiple medical centers in China. The analysis focused on dose effects of HCQ on https://t.co/BuHoMDwpuP
Dr. John Cush RheumNow ( View Tweet)
Sucutaneous anifrolumab? Phase III TULIP-SC trial in SLE patients showed SC anifrolumab (Saphnelo) significantly reducted lupus disease activity compared to placebo. https://t.co/vvI2av2vAJ https://t.co/0V1wsmFk0N

Links:

Dr. John Cush RheumNow ( View Tweet)
Equal Safety of JAK Inhibitors and TNF Inhibitors JAMA has published a systematic review and meta-analysis of head-to-head studies showing there was no meaningful difference in safety events observed when taking either JAK inhibitor (JAKi) vs TNF antagonist (TNFi) therapies for https://t.co/DTux5QdETS
Dr. John Cush RheumNow ( View Tweet)
STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia Deane et al has published the results of the STOP-RA trial, demonstrating that 12 months of hydroxychloroquine (HCQ) did not prevent the development of clinical RA at 36 months. https://t.co/wsnc9uZi1P https://t.co/MwZJAQs7Rt

Links:

Dr. John Cush RheumNow ( View Tweet)
🆕 ILD (Part II): advanced insights 🫁 Multidisciplinary management 💊 Treatment strategies 📊 Prognosis & monitoring 🧑⚕️ What rheums should know next ⬇️ Download & learn more: https://t.co/XNmbcfqKKF Created by @MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/Yhlw3nGsDh

Links:

Dr. John Cush RheumNow ( View Tweet)
Methyl-prednisolone plus methotrexate-based regime vs prednisone-based standard of care for giant cell arteritis: a propensity score study https://t.co/kmLy6NXFO1

Links:

Luis Caminal caminalm ( View Tweet)

Optimal glucocorticoid therapy in lupus nephritis 🔓https://t.co/e6SjmOrRpw ➡️This review provides an in-depth analysis of glucocorticoid therapy for lupus nephritis, a severe manifestation of systemic lupus erythematosus that affects up to 51.7% of patients https://t.co/JftCQiFif1

Links:

NDT NDTsocial ( View Tweet)
Infections cause high morbidity & mortality in our immunocompromised rheum patients: vaccinations are essential to keep them healthy. Best time to administer vaccines? 1. Before immunosuppression 2 during periods of dz control 3. >1 vaccines need pt input @LCalabreseDO #CCRW25 https://t.co/oBgXlIk1TY

Links:

TheDaoIndex KDAO2011 ( View Tweet)
This is a pivotal trial. 187 pt w/ incomplete lupus (ANA+ plus 1-2 criteria, but not qualifying as SLE) shows that HCQ does not prevent progression to SLE! Congrats to these researchers lead by Nancy Olsen et al. https://t.co/NnrA8ohiGX

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×